These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

796 related items for PubMed ID: 23500084

  • 1. Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age.
    Kondalsamy-Chennakesavan S, Hackethal A, Bowtell D, Australian Ovarian Cancer Study Group, Obermair A.
    Gynecol Oncol; 2013 Jun; 129(3):467-71. PubMed ID: 23500084
    [Abstract] [Full Text] [Related]

  • 2. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.
    Sandri MT, Bottari F, Franchi D, Boveri S, Candiani M, Ronzoni S, Peiretti M, Radice D, Passerini R, Sideri M.
    Gynecol Oncol; 2013 Feb; 128(2):233-8. PubMed ID: 23200911
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
    Karlsen MA, Sandhu N, Høgdall C, Christensen IJ, Nedergaard L, Lundvall L, Engelholm SA, Pedersen AT, Hartwell D, Lydolph M, Laursen IA, Høgdall EV.
    Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
    [Abstract] [Full Text] [Related]

  • 4. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
    Richards A, Herbst U, Manalang J, Pather S, Saidi S, Tejada-Berges T, Tan K, Williams P, Carter J.
    Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
    [Abstract] [Full Text] [Related]

  • 5. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.
    Romagnolo C, Leon AE, Fabricio ASC, Taborelli M, Polesel J, Del Pup L, Steffan A, Cervo S, Ravaggi A, Zanotti L, Bandiera E, Odicino FE, Scattolo N, Squarcina E, Papadakis C, Maggino T, Gion M.
    Gynecol Oncol; 2016 May; 141(2):303-311. PubMed ID: 26801941
    [Abstract] [Full Text] [Related]

  • 6. The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass.
    Chan KK, Chen CA, Nam JH, Ochiai K, Wilailak S, Choon AT, Sabaratnam S, Hebbar S, Sickan J, Schodin BA, Sumpaico WW.
    Gynecol Oncol; 2013 Feb; 128(2):239-44. PubMed ID: 23063998
    [Abstract] [Full Text] [Related]

  • 7. Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women.
    Cho HY, Park SH, Park YH, Kim HB, Kang JB, Hong SH, Kyung MS.
    J Korean Med Sci; 2015 Dec; 30(12):1777-83. PubMed ID: 26713052
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses.
    Fawzy A, Mohamed MR, Ali MA, Abd El-Magied MH, Helal AM.
    Asian Pac J Cancer Prev; 2016 Dec; 17(1):323-33. PubMed ID: 26838232
    [Abstract] [Full Text] [Related]

  • 10. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.
    Lycke M, Kristjansdottir B, Sundfeldt K.
    Gynecol Oncol; 2018 Oct; 151(1):159-165. PubMed ID: 30149898
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?
    Montagnana M, Danese E, Ruzzenente O, Bresciani V, Nuzzo T, Gelati M, Salvagno GL, Franchi M, Lippi G, Guidi GC.
    Clin Chem Lab Med; 2011 Mar; 49(3):521-5. PubMed ID: 21288178
    [Abstract] [Full Text] [Related]

  • 14. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
    Kristjansdottir B, Levan K, Partheen K, Sundfeldt K.
    Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
    [Abstract] [Full Text] [Related]

  • 15. Diagnostic performance of human epididymis protein 4 compared to a combination of biophysical and biochemical markers to differentiate ovarian endometriosis from epithelial ovarian cancer in premenopausal women.
    Nikolova T, Zivadinovic R, Evtimovska N, Klisarovska V, Stanojevic M, Georgievska J, Nikolova N.
    J Obstet Gynaecol Res; 2017 Dec; 43(12):1870-1879. PubMed ID: 29027715
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women.
    Fujiwara H, Suzuki M, Takeshima N, Takizawa K, Kimura E, Nakanishi T, Yamada K, Takano H, Sasaki H, Koyama K, Ochiai K.
    Tumour Biol; 2015 Feb; 36(2):1045-53. PubMed ID: 25326813
    [Abstract] [Full Text] [Related]

  • 17. Modification of cut-off values for HE4, CA125 and the ROMA algorithm for early-stage epithelial ovarian cancer detection: Results from 1021 cases in South China.
    Xu Y, Zhong R, He J, Ding R, Lin H, Deng Y, Zhou L, Li X, Jiang J, Bao Y, Luo X, Duan C.
    Clin Biochem; 2016 Jan; 49(1-2):32-40. PubMed ID: 26285075
    [Abstract] [Full Text] [Related]

  • 18. Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses.
    Chen X, Zhou H, Chen R, He J, Wang Y, Huang L, Sun L, Duan C, Luo X, Yan H.
    Clin Chim Acta; 2015 Feb 02; 440():57-63. PubMed ID: 25447698
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.